Duchenne Muscular Dystrophy (DMD): Clinical Trials

16 trials for Duchenne Muscular Dystrophy (DMD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 recruiting, 2 active not recruiting, 2 not yet recruiting. 16 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 5, Recruiting 4, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2, Enrolling by invitation 1
Phase 15Recruiting 3, Active not recruiting 1, Completed 1

Follow Duchenne Muscular Dystrophy (DMD): new trials by email Literature Review of Duchenne Muscular Dystrophy (DMD) trials Research Report on Duchenne Muscular Dystrophy (DMD)

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingVanderbilt University Medical Center302026-12-012026-11-12
A Trial to Investigate the Efficacy and Safety of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
Tegacorat - Duchenne Muscular Dystrophy (DMD)
Phase 2Not yet recruitingGrünenthal GmbH362026-11-302026-11-17
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
ENTR-601-44, ENTR-601-45 - Duchenne Muscular Dystrophy (DMD)
Phase 2Not yet recruitingEntrada Therapeutics, Inc.802026-08-012026-07-02
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
BMN 351 - Duchenne Muscular Dystrophy (DMD)
Phase 2Enrolling by invitationBioMarin Pharmaceutical182026-04-202026-07-24
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
SAT-3247 - Duchenne Muscular Dystrophy (DMD)
Phase 2RecruitingSatellos Bioscience, Inc.302025-09-252026-11-19
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
ENTR-601-45, ENTR-601-45 - matching placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingEntrada Therapeutics, Inc.242025-08-302026-08-13
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
ENTR-601-44, ENTR-601-44 - matching placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingEntrada Therapeutics, Inc.242025-06-302026-08-13
A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
IV infusion, Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 2WithdrawnPepGen Inc2024-12-172025-06-24
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
DYNE-251, Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2Active not recruitingDyne Therapeutics862022-08-122026-08-11
Extension Study of NS-089/NCNP-02 in DMD
NS-089/NCNP-02 - Duchenne Muscular Dystrophy (DMD)
Phase 2Active not recruitingNippon Shinyaku Co., Ltd.62021-06-232025-07-20
Twice Weekly Steroids and Exercise as Therapy for DMD
Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids - Duchenne Muscular Dystrophy (DMD)
Phase 2CompletedUniversity of Florida212020-07-302026-03-13
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
eteplirsen - Duchenne Muscular Dystrophy (DMD)
Phase 2CompletedSarepta Therapeutics, Inc.332015-06-302021-01-25
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
Prednisone, Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 2WithdrawnAnn & Robert H Lurie Children's Hospital of Chicago2014-11-012015-02-18
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
Givinostat - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2CompletedItalfarmaco202013-04-012023-11-07
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
AVI-4658 (Eteplirsen) - Duchenne Muscular Dystrophy (DMD)
Phase 2CompletedSarepta Therapeutics, Inc.122012-02-272020-03-30
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
idebenone, placebo - Duchenne Muscular Dystrophy (DMD)
Phase 2CompletedSanthera Pharmaceuticals212005-10-012011-08-01

Narrower conditions

Muscular Dystrophy, Duchenne (16)  ·  Muscular Dystrophies (2)  ·  Neuromuscular Diseases (1)  ·  Obesity (1)  ·  Rare Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16)  ·  Genetic Diseases, Inborn (16)  ·  Genetic Diseases, X-Linked (16)  ·  Muscular Diseases (16)  ·  Muscular Disorders, Atrophic (16)  ·  Musculoskeletal Diseases (16)  ·  Nervous System Diseases (16)  ·  Neuromuscular Diseases (15)  ·  Muscular Dystrophies (14)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Body Weight (1)  ·  Disease Attributes (1)  ·  Nutrition Disorders (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Overnutrition (1)

Interventions

Prednisone (2)  ·  eteplirsen (2)  ·  Glucocorticoids (1)  ·  Infusions, Intravenous (1)  ·  givinostat (1)  ·  givinostat hydrochloride (1)  ·  idebenone (1)  ·  semaglutide (1)

Sponsors

Entrada Therapeutics, Inc. (3)  ·  Sarepta Therapeutics, Inc. (2)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  BioMarin Pharmaceutical (1)  ·  Dyne Therapeutics (1)  ·  Grünenthal GmbH (1)  ·  Italfarmaco (1)  ·  Nippon Shinyaku Co., Ltd. (1)  ·  PepGen Inc (1)  ·  Santhera Pharmaceuticals (1)  ·  Satellos Bioscience, Inc. (1)  ·  University of Florida (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (7)  ·  Italy (6)  ·  Belgium (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  Netherlands (3)  ·  Australia (2)  ·  Canada (1)  ·  Ireland (1)  ·  Japan (1)  ·  South Korea (1)  ·  Turkey (Türkiye) (1)

Top investigators

Enrico Bertini, MD (1)  ·  Gunnar Buyse, MD PhD (1)  ·  Nancy Kuntz, MD (1)  ·  Tanja Taivassalo, MD (1)

Results publications

PMID 21435876, PMID 26573217, PMID 27566866

NIH funding

2023 (2), 2025 (1)